van Meerten T, Hagenbeek A
Department of Haematology, University Medical Centre Utrecht, Utrecht, the Netherlands.
Neth J Med. 2009 Jul-Aug;67(7):251-9.
Targeting the CD20 antigen on B lymphocytes with the monoclonal antibody rituximab has greatly improved the outcome of patients with B-cell malignancies. Despite the success of rituximab, resistance occurs in about half of the patients, resulting in non-response to treatment or early relapse of the original disease. A better understanding of the mechanism of rituximab resistance has lead to the development of novel, improved anti-CD20 antibodies. This review describes the development of CD20-targeted therapy from its historical background towards the next generation of anti-CD20 monoclonal antibodies and explains new strategies to overcome resistance.
用单克隆抗体利妥昔单抗靶向B淋巴细胞上的CD20抗原，极大地改善了B细胞恶性肿瘤患者的治疗效果。尽管利妥昔单抗取得了成功，但约一半的患者会出现耐药性，导致治疗无反应或原发病早期复发。对利妥昔单抗耐药机制的深入了解促使了新型、改良抗CD20抗体的研发。本文综述了CD20靶向治疗从其历史背景到下一代抗CD20单克隆抗体的发展历程，并解释了克服耐药性的新策略。
